**Name of Journal:** *World Journal of Gastrointestinal Surgery*

**Manuscript NO:** 89950

**Manuscript Type:** EDITORIAL

**Prospects in the application of ultrasensitive chromosomal aneuploidy detection in precancerous lesions of gastric cancer**

Qian ST *et al*. UCAD application prospects in PLGC

Su-Ting Qian, Fei-Fei Xie, Hao-Yu Zhao, Qing-Sheng Liu, Dan-Li Cai

**Su-Ting Qian, Fei-Fei Xie, Hao-Yu Zhao,** Department of Digestive, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou 310007, Zhejiang Province, China

**Qing-Sheng Liu,** Science and Education Section, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou 310007, Zhejiang Province, China

**Dan-Li Cai,** Intensive Care Unit, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 311122, Zhejiang Province, China

**Author contributions:** Cai DL designed the overall concept and outline of the manuscript; Qian ST contributed to the design and writing of the manuscript; Xie FF, Zhao HY,andLiu QS contributed to the editing the manuscript, illustrations, and review of literature.

**Corresponding author: Dan-Li Cai, MM, Assistant Chief Physician,** Intensive Care Unit, The First Affiliated Hospital of Zhejiang Chinese Medical University, No. 1 Gaojiao Road, Yuhang District, Hangzhou 311122, Zhejiang Province, China. 13858159603@139.com

**Received:** November 18, 2023

**Revised:** December 11, 2023

**Accepted:** December 26, 2023

**Published online:**

**Abstract**

Gastric cancer (GC) is a prevalent malignant tumor within the digestive system, with over 40% of new cases and deaths related to GC globally occurring in China. Despite advancements in treatment modalities, such as surgery supplemented by adjuvant radiotherapy or chemotherapeutic agents, the prognosis for GC remains poor. New targeted therapies and immunotherapies are currently under investigation, but no significant breakthroughs have been achieved. Studies have indicated that GC is a heterogeneous disease, encompassing multiple subtypes with distinct biological characteristics and roles. Consequently, personalized treatment based on clinical features, pathologic typing, and molecular typing is crucial for the diagnosis and management of precancerous lesions of gastric cancer (PLGC). Current research has categorized GC into four subtypes: Epstein-Barr virus-positive, microsatellite instability, genome stability, and chromosome instability (CIN). Technologies such as multi-omics analysis and gene sequencing are being employed to identify more suitable novel testing methods in these areas. Among these, ultrasensitive chromosomal aneuploidy detection (UCAD) can detect CIN at a genome-wide level in subjects using low-depth whole genome sequencing technology, in conjunction with bioinformatics analysis, to achieve qualitative and quantitative detection of chromosomal stability. This editorial reviews recent research advancements in UCAD technology for the diagnosis and management of PLGC.

**Key Words:** Gastric cancer; Precancerous lesions of gastric cancer; Molecular typing; Ultrasensitive chromosomal aneuploidy detection; Adjuvant therapy; Application prospects

Qian ST, Xie FF, Zhao HY, Liu QS, Cai DL. Prospects in the application of ultrasensitive chromosomal aneuploidy detection in precancerous lesions of gastric cancer. *World J Gastrointest Surg* 2023; In press

**Core Tip:** The purpose of this editorial is to provide an overview of the current diagnostic and therapeutic guidelines for gastric precancerous lesions, and to explore the potential clinical application of ultrasensitive chromosomal aneuploidy detection in the field of gastric cancer prevention and control. By doing so, this article aims to advance future research in this area.

**INTRODUCTION**

Gastric cancer (GC) is the third leading cause of cancer-related deaths globally, with the highest incidence particularly in East Asia, Central, and Eastern Europe[1]. The number of incidences of GC will likely increase in the future due to higher socioeconomic status and aging populations[2]. In recent times, the prevalence of pan-cancer screening and gastroscopy has led to early identification and treatment of a growing number of patients in the initial (gastric pre-cancer) phase. The use of endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) has significantly enhanced patient survival. However, the majority of cases are still diagnosed at an advanced stage, resulting in the majority of patients succumbing to GC[3]. Despite the advancements in medical technology, a significant number of patients are reluctant to undergo endoscopy. Thus, researchers are still actively investigating the stages of precancerous lesions of gastric cancer (PLGC) and searching for more expedited and streamlined diagnostic approaches. These remain pressing issues in current PLGC research.

Due to the subtle symptoms of GC, the condition is typically discovered at an advanced stage in patients who seek medical attention, leading to higher mortality rates and a poorer prognosis. Advancements in next-generation sequencing and other genomic technologies have spurred new research into the molecular characteristics of GC[4]. Gene mutations, chromosomal aberrations, differential gene expression, and epigenetic alterations are some of the genetic and epigenetic factors that influence the pathogenesis of GC. Thus, The Cancer Genome Atlas (TCGA) network proposes a four-subtype classification scheme for GC based on the molecular biology of potential tumors for each subtype, including Epstein-Barr virus (EBV)-positive, microsatellite instability (MSI), genome stability (GS) type, and chromosome instability (CIN) type[5]. One of the most frequent genetic alterations is CIN, often referred to as chromosomal copy number aberration (CNA). The ultrasensitive chromosomal aneuploidy detection (UCAD) technology relies on low-coverage whole-genome sequencing (LC-WGS) to diagnose or predict a patient's tumor risk by identifying chromosomal CNA in a sample.

The purpose of this editorial is to offer an updated overview of the established diagnostic and treatment criteria for gastric precancerous lesions. It covers emerging diagnostic and treatment techniques, and explores the potential for deploying UCAD technology as an early diagnostic tool.

**PLGC: EARLY PREVENTION AND CURRENT STATUS IN CLINICAL DIAGNOSIS**

At this stage, the clinical consensus of PLGC can be categorized into atrophy (loss of gastric glands), intestinal metaplasia (replacement of gastric epithelium by intestinal epithelium), and dysplasia (intraepithelial neoplasia, including low-grade intraepithelial neoplasia and high-grade intraepithelial neoplasia)[6].

*Helicobacter pylori* (*H. pylori*) infection, the most common chronic bacterial infection in humans, is the strongest known risk factor for gastric carcinogenesis. Chronic and persistent inflammation resulting from *H. pylori* in the stomach lining may give rise to progressive atrophic gastritis and intestinal metaplasia[7].

*H. pylori* strains have a cytotoxin-associated gene A (CagA) that encodes a 120-140 kDa CagA protein, an oncoprotein that affects tumor cells. It also contains additional virulence factors, including vacuolating cytotoxin A, duodenal ulcer-promoting gene A protein, outer inflammatory protein A, and gamma-glutamyl transpeptidase. Most individuals infected with *H. pylori* are asymptomatic, yet have an increased risk of developing peptic ulcers or gastric adenocarcinoma[8,9].

In addition to *H. pylori*, age, tobacco and alcohol consumption, high salt intake and a diet low in fruits and vegetables, familial susceptibility, previous gastric surgery, and pernicious anemia are all relevant risk factors. It is clear that control of the above risk factors is an important basis for the prevention of PLGC[10].

Screening for cancer risk factors is a straightforward process; however, precisely identifying at-risk groups for early screening poses a challenge. To mitigate this, it is essential to implement effective strategies that optimize the selection of individuals who are most likely to benefit from early screening. The primary diagnostic method currently used is endoscopic biopsy, with the challenge being the identification of individuals at risk of developing PLGC in the absence of positive signs[11]. It is apparent that endoscopy, as an invasive medical examination, receives limited acceptance from certain demographics who may also be restricted by underlying diseases and age. The development and implementation of novel early cancer diagnostic tools must adhere to the reliability, reproducibility, and cost control standards set by the World Health Organization. Furthermore, they must prioritize ease of use and patient comfort[]12].

Available studies have shown a significant level of heterogeneity in the histopathology and molecular biology of GC. Screening for hallmark molecules of PLGC involves identifying genetic or protein markers that can be used for early diagnosis and prognostic determination. Most of the screened molecules such as oncogenes, intercellular adhesion molecules, growth factors, and certain hormone receptors exhibit deficiencies in sensitivity, specificity, and reliability, with only a few being recognized.

A paper published in Nature a few years ago by TCGA proposed dividing GC into four subtypes based on molecular characteristics[13].

EBV-positive phenotype is frequently associated with PIK3CA mutations, DNA hypermethylation, and amplification of JAK2, CD274, and PDCD1LG2. MSI is a type characterized by a high mutation rate, including mutations in genes that activate oncogene signaling pathways. The GS type, which occurs most often in the histologically diffuse form, is caused by mutations in RHOA or fusions of GTPase-activating protein genes in the THO family. CIN type, which has the hallmark heterozygous chromosomes and in situ amplification of the receptor lysine kinase.

The conventional method of devising treatment plans based on tumor phenotypic characteristics will be replaced by a mode that considers gene alterations instead[14]. Utilizing single gene expression changes can direct targeted medication therapy, which is a more rational, efficient and personalized mode of treatment compared to chemotherapy for the same morphology type. Additionally, multi-gene detection will become an essential research area[15].

**GUIDELINES FOR THE TREATMENT OF PLGC: STANDARDS AND DEVELOPMENTS**

Early GC without lymph node metastasis may be treated through endoscopic or surgical means, depending on the extent of tumor invasion. Adjuvant radiotherapy or chemotherapy is not necessary after surgery.

Locally advanced GC or early GC with lymph node metastasis should be managed using comprehensive surgical treatment. The decision of direct radical surgery *vs* preoperative neoadjuvant chemotherapy, before radical surgery, depends on the depth of tumor invasion and whether or not lymph node metastasis is present. For patients with locally advanced GC who have undergone successful radical surgery, adjuvant treatment planning (including adjuvant chemotherapy and, if necessary, adjuvant chemoradiotherapy) should be based on the postoperative pathological staging.

Recurrent or metastatic GC requires comprehensive treatment consisting mainly of medication. Palliative surgery, radiotherapy, interventional therapy, and local therapies should also be administered as needed, along with optimal supportive therapies, including analgesia, stenting, and nutrition support. It is essential to give supportive therapies actively at the appropriate time[16].

***Endoscopic techniques***

EMR is the endoscopic removal of mucosal lesions, in whole or in part, for the diagnosis and treatment of superficial tumors of the gastrointestinal tract[17].

ESD is a new technology developed on the basis of EMR. According to the lesions with different parts, sizes and infiltration depths, special electrocautery knives such as IT knives, Dual knives, Hook knives, *etc.* are selected for endoscopic gradual separation of tissues between the mucous membrane layer and the intrinsic muscular layer, and finally the lesion mucous membrane and submucosal layer are completely removed[18].

Other endoscopic treatments include laser therapy, argon knife, microwave therapy, *etc.* They can only remove the tumor, but cannot obtain complete pathological specimens or be sure that the tumor is completely removed. Therefore, they are mostly used for the treatment of precancerous gastric lesions and require close follow-up after treatment, and are not recommended as the first choice of treatment for early GC[19,20].

***Surgery******and chemotherapy***

PLGC surgery is divided into radical surgery and non-radical surgery. Radical surgery should completely remove the primary lesion and thoroughly clear the regional lymph nodes, mainly including standard surgery, modified surgery and extended surgery; non-radical surgery mainly includes palliative surgery and tumor reduction surgery[21,22].

Chemotherapy is divided into palliative chemotherapy, adjuvant chemotherapy, neoadjuvant chemotherapy, and conversion therapy.

Neoadjuvant chemotherapy is recommended for locally advanced GC without distant metastases (T3/4, N+). The regimen should consist of a two-drug combination of platinum and fluorouracil or a three-drug combination based on the two-drug regimen combined with paclitaxel. It should not be used as a single agent[11].

The GC management process is shown in Figure 1.

**UCAD APPLICATION PROSPECTS**

In the article "*Hallmarks of cancer: The next generation*" in *Cell*, the authors systematically summarized various hallmarks of cancer development. They highlighted genomic instability (or chromosomal instability) as the fundamental cause of cancer development, present in almost all malignant tumors. Thus, genomic instability is considered the root cause of cancer[23].

CIN is a feature of certain cells that results in the production of daughter cells that have an altered chromosome number or structure. This is a common feature in cancer cells. The fundamental aspects of chromosomal instability include changes in chromosome copy number, which leads to the emergence of cells with aneuploidy, as well as alterations in chromosome structure. These changes can include polyploidy, chromosomal translocations, genomic chaos, and non-clonal chromosomal aberrations[24].

The mechanism behind cancer cells is the irregular distribution of chromosomes during mitosis in zygote cells and the persistence of errors in chromosome segregation. This leads to modifications in chromosome copy number, as well as intrachromosomal segment amplification or deletion[25].

The substantial loss, gain, and rearrangement of DNA accumulate, resulting in chromosomal instability. This instability leads to extensive genomic complexity, which is a hallmark of cancer that is either present or expected. Chromosomal instability is strongly associated with tumor staging, metastasis, poor prognosis, and treatment resistance. This includes the loss or amplification of driver genes, focal rearrangements, extrachromosomal DNA, micronucleus formation, and the activation of innate immune signaling. These mechanisms lead to the diversification of tumor subclones in terms of space and time. This facilitates metastasis, accelerates the phenotypic adaptation of tumors, promotes cellular immortality, the escape from immune surveillance, and the development of resistance to drug treatments, among other processes[26].

CIN has been extensively studied as an innovative test. Using patient-derived tumor organoids to imitate colorectal cancer, researchers confirmed the existence of anaphase chromatin bridges in colorectal cancer cell lines. Causes consisted of insufficient disassembly of sister chromatids, telomere fusion producing bicentric chromosomes, and incomplete replication. These manifestations of CIN are prevalent in organs resembling colorectal cancer and have a significant impact on tumor evolution and therapeutic response. The levels of CIN and tolerance to mitotic errors play a crucial role in shaping the aneuploid landscapes and karyotypic heterogeneity[27].

Copy number and structural changes due to CIN are common features of multiple myeloma (MM). Primary and secondary genetic events caused by CIN lead to an increase in malignant plasma cell genomic instability by interfering with cell cycle checkpoints, thus accelerating proliferation. Thus, an assessment of CIN in MM and its precursor states may help to mitigate the progression of symptomatic disease and the risk of relapse[28].

CIN plays a role in the development of some subtypes of diffuse infiltrating gliomas. In isocitrate dehydrogenase-mutant astrocytomas, copy number variation (CNV) levels rise overall with tumor grade, duration, and proximity of infiltrating cells within the same tumor. The detection of CIN through CNV, DNA methylation, and/or gene expression profiling can effectively identify gliomas influenced by this molecular mechanism[29].

UCAD is a cutting-edge approach for identifying cellular chromosomal instability. This technique leverages body fluid free DNA or tissue genomic DNA as a template and utilizes LC-WGS, together with bioinformatics analysis, to identify chromosomal instability at the genome-wide scale. This technique has the potential to aid in the detection of tumors, monitor the effectiveness of treatment, and assess the likelihood of recurrence and metastasis. Samples including peripheral blood, exfoliated cells, menstrual blood, fresh and frozen tissues, formalin-fixed paraffin-embedded, urine, and others, can be analyzed for diagnostic purposes.

UCAD has been applied in clinical studies at this stage. Ye *et al*[30] collected samples of pancreatic cystic fluid from 102 patients with pancreatic cystic neoplasms (PCN) and employed UCAD to examine distinct CIN characteristics among different types of PCN. The deletion of chr3p and chr6p was used to define subtypes of serous cystadenoma. Meanwhile, the gain of chr1q and chr8q was associated with latent malignant PCN and facilitated the detection of high-risk intraductal papillary mucinous neoplasm.

Wang *et al*[31] collected plasma samples from 47 patients suspected of having lesions in the biliary tract. They utilized UCAD to analyze free DNA for CNV analysis through low-coverage whole genome sequencing. The results demonstrated the most frequent copy number gains in chr3q (7/29) and chr8q (6/29), with the most prevalent copy number losses noted in chr7p (6/29), chr17p (6/29), and chr19p (6/29). The sensitivity and specificity of the plasma CNV assay for the diagnosis of biliary tract cancer were 89.7% and 88.9%, respectively.

Feng *et al*[32] obtained 196 plasma samples from two groups of patients: a discovery cohort of individuals with PLC who were not eligible for surgery, and a validation cohort of patients who underwent pathologically confirmed hepatectomies. Of the 172 individuals, 22 (95.7%) surgically ineligible hepatocellular carcinomas were identified as having CNV in at least 1 of the 29 segments. 54 (69.4%) of the hepatocellular carcinomas eligible for surgery received positive screenings, and subsequently, confirmed to be cancerous by pathologic examination. Additionally, 26/27 non-cancers were identified with negative screenings.

Ye *et al*[33] gathered mucosal samples from 40 patients with GC from the hospital. 20 were microbiome-enriched, 5 tested positive for EBV DNA, and 15 had *H. pylori* DNA. Meanwhile, 20 of the samples were found to have CIN. UCAD can be used to identify 3 distinct subtypes of GC in the Chinese population, providing valuable guidance for future research on GC treatment and prevention. UCAD can identify three distinct subtypes of GC in the Chinese population. This finding could provide valuable guidance for further research on the prevention and treatment of GC.

**CONCLUSION**

In recent years, there has been an acceleration in precision treatment for PLGC, however, obstacles remain. The evolving endoscopic technology and surgical treatment have not sufficiently addressed the high recurrence rate after surgery. While there is a clinical benefit trend in anti-HER2 therapy and anti-CLDN18.2 monoclonal antibody therapy, additional research is necessary to optimize treatment and maximize patient benefit[34,35]. Early diagnostic treatment remains a pressing and essential need for improvement with a significant demand for less invasive or non-invasive testing and highly specific biomarkers[36]. Research efforts must focus on developing more convenient, comfortable, and highly accurate diagnostic tests, like tests on body fluids such as peripheral blood, urine or saliva, and gastric fluids, for early assessment of the likelihood of patient progression. Early treatment is critical for reducing the risk of developing GC.

In this context, UCAD has been researched and applied as a new test for early prevention in patients with positive early sequencing results or for gastroscopy and treatment to timely remove lesions at a stage when PLGC has not progressed. With the gradual decrease in the cost of second-generation sequencing, UCAD assays are expected to become more cost-effective in the near future. Meanwhile, the UCAD assay can capture both human and microbiome DNA while detecting specimens from mucosal, blood, and urine sources. This convenience, comfort, and information make it a superior technology for GC subtyping compared to other methods. Overall, this new approach may improve diagnostic and therapeutic strategies for PLGC in a cost-effective manner, achieving true precision.

**ACKNOWLEDGEMENTS**

We gratefully acknowledge the kind cooperation of all authors in the preparation of this paper.

**REFERENCES**

1 **Röcken C**. Predictive biomarkers in gastric cancer. *J Cancer Res Clin Oncol* 2023; **149**: 467-481 [PMID: 36260159 DOI: 10.1007/s00432-022-04408-0]

2 **Smyth EC**, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. *Lancet* 2020; **396**: 635-648 [PMID: 32861308 DOI: 10.1016/S0140-6736(20)31288-5]

3 **Pimentel-Nunes P**, Libânio D, Marcos-Pinto R, Areia M, Leja M, Esposito G, Garrido M, Kikuste I, Megraud F, Matysiak-Budnik T, Annibale B, Dumonceau JM, Barros R, Fléjou JF, Carneiro F, van Hooft JE, Kuipers EJ, Dinis-Ribeiro M. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. *Endoscopy* 2019; **51**: 365-388 [PMID: 30841008 DOI: 10.1055/a-0859-1883]

4 **Zeng Y**, Jin RU. Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer. *Semin Cancer Biol* 2022; **86**: 566-582 [PMID: 34933124 DOI: 10.1016/j.semcancer.2021.12.004]

5 **Yuen ST**, Leung SY. Genomics Study of Gastric Cancer and Its Molecular Subtypes. *Adv Exp Med Biol* 2016; **908**: 419-439 [PMID: 27573784 DOI: 10.1007/978-3-319-41388-4\_21]

6 **Gullo I**, Grillo F, Mastracci L, Vanoli A, Carneiro F, Saragoni L, Limarzi F, Ferro J, Parente P, Fassan M. Precancerous lesions of the stomach, gastric cancer and hereditary gastric cancer syndromes. *Pathologica* 2020; **112**: 166-185 [PMID: 33179620 DOI: 10.32074/1591-951X-166]

7 **Toyoshima O**, Nishizawa T, Koike K. Endoscopic Kyoto classification of Helicobacter pylori infection and gastric cancer risk diagnosis. *World J Gastroenterol* 2020; **26**: 466-477 [PMID: 32089624 DOI: 10.3748/wjg.v26.i5.466]

8 **de Brito BB**, da Silva FAF, Soares AS, Pereira VA, Santos MLC, Sampaio MM, Neves PHM, de Melo FF. Pathogenesis and clinical management of Helicobacter pylori gastric infection. *World J Gastroenterol* 2019; **25**: 5578-5589 [PMID: 31602159 DOI: 10.3748/wjg.v25.i37.5578]

9 **FitzGerald R**, Smith SM. An Overview of Helicobacter pylori Infection. *Methods Mol Biol* 2021; **2283**: 1-14 [PMID: 33765303 DOI: 10.1007/978-1-0716-1302-3\_1]

10 **Eusebi LH**, Telese A, Marasco G, Bazzoli F, Zagari RM. Gastric cancer prevention strategies: A global perspective. *J Gastroenterol Hepatol* 2020; **35**: 1495-1502 [PMID: 32181516 DOI: 10.1111/jgh.15037]

11 **Hoshi H**. Management of Gastric Adenocarcinoma for General Surgeons. *Surg Clin North Am* 2020; **100**: 523-534 [PMID: 32402298 DOI: 10.1016/j.suc.2020.02.004]

12 **Hu Y**, Lv X, Wei W, Li X, Zhang K, Zhu L, Gan T, Zeng H, Yang J, Rao N. Quantitative Analysis on Molecular Characteristics Evolution of Gastric Cancer Progression and Prognosis. *Adv Biol (Weinh)* 2023; **7**: e2300129 [PMID: 37357148 DOI: 10.1002/adbi.202300129]

13 **Cancer Genome Atlas Research Network**. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature* 2014; **513**: 202-209 [PMID: 25079317 DOI: 10.1038/nature13480]

14 **Wadowska K**, Bil-Lula I, Trembecki Ł, Śliwińska-Mossoń M. Genetic Markers in Lung Cancer Diagnosis: A Review. *Int J Mol Sci* 2020; **21** [PMID: 32604993 DOI: 10.3390/ijms21134569]

15 **Bartlett J**, Amemiya Y, Arts H, Bayani J, Eng B, Grafodatskaya D, Kamel Reid S, Lariviere M, Lo B, McClure R, Mittal V, Sadikovic B, Sadis S, Seth A, Smith J, Zhang X, Feilotter H. Multisite verification of the accuracy of a multi-gene next generation sequencing panel for detection of mutations and copy number alterations in solid tumours. *PLoS One* 2021; **16**: e0258188 [PMID: 34597339 DOI: 10.1371/journal.pone.0258188]

16 **Ajani JA**, D'Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, Farjah F, Gerdes H, Gibson MK, Hochwald S, Hofstetter WL, Ilson DH, Keswani RN, Kim S, Kleinberg LR, Klempner SJ, Lacy J, Ly QP, Matkowskyj KA, McNamara M, Mulcahy MF, Outlaw D, Park H, Perry KA, Pimiento J, Poultsides GA, Reznik S, Roses RE, Strong VE, Su S, Wang HL, Wiesner G, Willett CG, Yakoub D, Yoon H, McMillian N, Pluchino LA. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2022; **20**: 167-192 [PMID: 35130500 DOI: 10.6004/jnccn.2022.0008]

17 **Ahmed Y**, Othman M. EMR/ESD: Techniques, Complications, and Evidence. *Curr Gastroenterol Rep* 2020; **22**: 39 [PMID: 32542462 DOI: 10.1007/s11894-020-00777-z]

18 **Liu Q**, Ding L, Qiu X, Meng F. Updated evaluation of endoscopic submucosal dissection versus surgery for early gastric cancer: A systematic review and meta-analysis. *Int J Surg* 2020; **73**: 28-41 [PMID: 31783166 DOI: 10.1016/j.ijsu.2019.11.027]

19 **Niknam N**, Obanor S, Lee LA. Endoscopic methods for the detection and treatment of gastric cancer. *Curr Opin Gastroenterol* 2022; **38**: 436-442 [PMID: 35881962 DOI: 10.1097/MOG.0000000000000867]

20 **Young E**, Philpott H, Singh R. Endoscopic diagnosis and treatment of gastric dysplasia and early cancer: Current evidence and what the future may hold. *World J Gastroenterol* 2021; **27**: 5126-5151 [PMID: 34497440 DOI: 10.3748/wjg.v27.i31.5126]

21 **Johnston FM**, Beckman M. Updates on Management of Gastric Cancer. *Curr Oncol Rep* 2019; **21**: 67 [PMID: 31236716 DOI: 10.1007/s11912-019-0820-4]

22 **Wang Y**, Zhang L, Yang Y, Lu S, Chen H. Progress of Gastric Cancer Surgery in the era of Precision Medicine. *Int J Biol Sci* 2021; **17**: 1041-1049 [PMID: 33867827 DOI: 10.7150/ijbs.56735]

23 **Hanahan D**, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011; **144**: 646-674 [PMID: 21376230 DOI: 10.1016/j.cell.2011.02.013]

24 **Kuang X**, Li J. Chromosome instability and aneuploidy as context-dependent activators or inhibitors of antitumor immunity. *Front Immunol* 2022; **13**: 895961 [PMID: 36003402 DOI: 10.3389/fimmu.2022.895961]

25 **Bach DH**, Zhang W, Sood AK. Chromosomal Instability in Tumor Initiation and Development. *Cancer Res* 2019; **79**: 3995-4002 [PMID: 31350294 DOI: 10.1158/0008-5472.CAN-18-3235]

26 **Drews RM**, Hernando B, Tarabichi M, Haase K, Lesluyes T, Smith PS, Morrill Gavarró L, Couturier DL, Liu L, Schneider M, Brenton JD, Van Loo P, Macintyre G, Markowetz F. A pan-cancer compendium of chromosomal instability. *Nature* 2022; **606**: 976-983 [PMID: 35705807 DOI: 10.1038/s41586-022-04789-9]

27 **Bolhaqueiro ACF**, Ponsioen B, Bakker B, Klaasen SJ, Kucukkose E, van Jaarsveld RH, Vivié J, Verlaan-Klink I, Hami N, Spierings DCJ, Sasaki N, Dutta D, Boj SF, Vries RGJ, Lansdorp PM, van de Wetering M, van Oudenaarden A, Clevers H, Kranenburg O, Foijer F, Snippert HJG, Kops GJPL. Ongoing chromosomal instability and karyotype evolution in human colorectal cancer organoids. *Nat Genet* 2019; **51**: 824-834 [PMID: 31036964 DOI: 10.1038/s41588-019-0399-6]

28 **Neuse CJ**, Lomas OC, Schliemann C, Shen YJ, Manier S, Bustoros M, Ghobrial IM. Genome instability in multiple myeloma. *Leukemia* 2020; **34**: 2887-2897 [PMID: 32651540 DOI: 10.1038/s41375-020-0921-y]

29 **Richardson TE**, Walker JM, Abdullah KG, McBrayer SK, Viapiano MS, Mussa ZM, Tsankova NM, Snuderl M, Hatanpaa KJ. Chromosomal instability in adult-type diffuse gliomas. *Acta Neuropathol Commun* 2022; **10**: 115 [PMID: 35978439 DOI: 10.1186/s40478-022-01420-w]

30 **Ye M**, Zhang B, Han X, Wei X, Wang Y, Cao W, Wu J, Chen C, Sun X, Sun K, Li H, Zhang Q, Liang T. Low-Pass Genomic Sequencing Reveals Novel Subtypes of Pancreatic Cystic Neoplasms. *Ann Surg Oncol* 2023; **30**: 5804-5812 [PMID: 37249723 DOI: 10.1245/s10434-023-13676-0]

31 **Wang X**, Fu XH, Qian ZL, Zhao T, Duan AQ, Ruan X, Zhu B, Yin L, Zhang YJ, Yu WL. Non-invasive detection of biliary tract cancer by low-coverage whole genome sequencing from plasma cell-free DNA: A prospective cohort study. *Transl Oncol* 2021; **14**: 100908 [PMID: 33059123 DOI: 10.1016/j.tranon.2020.100908]

32 **Feng S**, Ding Z, Wang J, Qian Z, Li S, Zhang C, Xin H, Liu S, Ding G, Hu M, Meng Y, Li N. Investigation of Plasma cell-free cancer genome chromosomal instability as a tool for targeted minimally invasive biomarkers for primary liver cancer diagnoses. *Cancer Med* 2020; **9**: 5075-5085 [PMID: 32458568 DOI: 10.1002/cam4.3142]

33 **Ye LP**, Mao XL, Zhou XB, Wang Y, Xu SW, He SQ, Qian ZL, Zhang XG, Zhai LJ, Peng JB, Gu BB, Jin XX, Song YQ, Li SW. Cost-effective low-coverage whole-genome sequencing assay for the risk stratification of gastric cancer. *World J Gastrointest Oncol* 2022; **14**: 690-702 [PMID: 35321281 DOI: 10.4251/wjgo.v14.i3.690]

34 **Janjigian YY**, Kawazoe A, Yañez P, Li N, Lonardi S, Kolesnik O, Barajas O, Bai Y, Shen L, Tang Y, Wyrwicz LS, Xu J, Shitara K, Qin S, Van Cutsem E, Tabernero J, Li L, Shah S, Bhagia P, Chung HC. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. *Nature* 2021; **600**: 727-730 [PMID: 34912120 DOI: 10.1038/s41586-021-04161-3]

35 **Zhong W**, Lu Y, Ma Z, He Y, Ding Y, Yao G, Zhou Z, Dong J, Fang Y, Jiang W, Wang W, Huang Y. Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers. *Front Immunol* 2022; **13**: 885424 [PMID: 35837391 DOI: 10.3389/fimmu.2022.885424]

36 **Necula L**, Matei L, Dragu D, Neagu AI, Mambet C, Nedeianu S, Bleotu C, Diaconu CC, Chivu-Economescu M. Recent advances in gastric cancer early diagnosis. *World J Gastroenterol* 2019; **25**: 2029-2044 [PMID: 31114131 DOI: 10.3748/wjg.v25.i17.2029]

**Footnotes**

**Conflict-of-interest statement:** All authors have no conflict-of-interest to disclose.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** November 18, 2023

**First decision:** December 6, 2023

**Article in press:**

**Specialty type:** Gastroenterology & hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Kotelevets SM, Russia **S-Editor:** Zhang H **L-Editor:** A **P-Editor:**

**Figure Legends**



**Figure 1 The gastric cancer management process.** EMR: Endoscopic mucosal resection; ESD: Endoscopic submucosal dissection; GC: Gastric cancer; PLGC: Precancerous lesions of gastric cancer; UCAD: Ultrasensitive chromosomal aneuploidy detection.